氨甲环酸治疗脑损伤的疗效:随机对照试验的荟萃分析
该系统评价与荟萃分析检索了 PubMed、EMbase、Web of science、EBSCO 和 Cochrane library 数据库,纳入 6 项关于氨甲环酸治疗创伤性脑损伤疗效的随机对照试验。与安慰剂组相比,氨甲环酸组死亡率显著降低(RR=0.91;95%CI 0.85 至 0.97;P=0.004),血肿扩大显著减少(RR=0.78;95%CI 0.61 至 0.99;P=0.04)。两组在神经外科手术(RR=0.99;95%CI 0.85 至 1.15;P=0.92)、颅外手术(RR=1.00;95%CI 0.97 至 1.04;P=0.99)、不良结局(GOS)(RR=0.72;95%CI 0.47 至 1.11;P=0.14)、肺栓塞(RR=1.86;95%CI 0.42 至 8.29;P=0.42)和深静脉血栓(RR=0.97;95%CI 0.64 至 1.47;P=0.88)方面无显著差异。
要点
- 在创伤性脑损伤患者中,与安慰剂相比,氨甲环酸降低死亡率(RR=0.91;95%CI 0.85 至 0.97;P=0.004)。
- 在创伤性脑损伤患者中,与安慰剂相比,氨甲环酸减少血肿扩大(RR=0.78;95%CI 0.61 至 0.99;P=0.04)。
- 氨甲环酸与安慰剂在神经外科手术需求方面无显著差异(RR=0.99;95%CI 0.85 至 1.15;P=0.92)。
- 氨甲环酸与安慰剂在不良结局(GOS)方面无显著差异(RR=0.72;95%CI 0.47 至 1.11;P=0.14)。
- 氨甲环酸与安慰剂在肺栓塞(RR=1.86;95%CI 0.42 至 8.29;P=0.42)和深静脉血栓(RR=0.97;95%CI 0.64 至 1.47;P=0.88)方面无显著差异。
适用人群与场景
- 创伤性脑损伤患者(纳入 6 项随机对照试验)。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析,纳入 6 项随机对照试验。
- 与安慰剂组相比,氨甲环酸组死亡率显著降低(RR=0.91;95%CI 0.85 至 0.97;P=0.004)。
- 与安慰剂组相比,氨甲环酸组血肿扩大显著减少(RR=0.78;95%CI 0.61 至 0.99;P=0.04)。
- 两组神经外科手术需求无显著差异(RR=0.99;95%CI 0.85 至 1.15;P=0.92)。
- 两组颅外手术需求无显著差异(RR=1.00;95%CI 0.97 至 1.04;P=0.99)。
- 两组不良结局(GOS)无显著差异(RR=0.72;95%CI 0.47 至 1.11;P=0.14)。
- 两组肺栓塞无显著差异(RR=1.86;95%CI 0.42 至 8.29;P=0.42)。
- 两组深静脉血栓无显著差异(RR=0.97;95%CI 0.64 至 1.47;P=0.88)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入 6 项随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于创伤性脑损伤患者,氨甲环酸与死亡率降低和血肿扩大减少相关,但神经外科手术需求、颅外手术需求及不良结局(GOS)与安慰剂相似。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tranexamic acid shows some treatment efficacy for traumatic brain injury. This systematic review and meta-analysis is conducted to investigate the efficacy of tranexamic acid for traumatic brain injury.
METHODS: The databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases are systematically searched for collecting the randomized controlled trials (RCTs) regarding the efficacy of tranexamic acid for traumatic brain injury.
RESULTS: This meta-analysis has included six RCTs. Compared with placebo group in patients with traumatic brain injury, tranexamic acid results in remarkably reduced mortality (risk ratio (RR) = 0.91; 95% confidence interval (CI) = 0.85 to 0.97; P = 0.004) and growth of hemorrhagic mass (RR = 0.78; 95% CI = 0.61 to 0.99; P = 0.04), but has no important impact on neurosurgery (RR = 0.99; 95% CI = 0.85 to 1.15; P = 0.92), extracranial surgery (RR = 1.00; 95% CI = 0.97 to 1.04; P = 0.99), unfavorable outcome (Glasgow Outcome Scale, GOS) (RR = 0.72; 95% CI = 0.47-1.11; P = 0.14), pulmonary embolism (RR = 1.86; 95% CI = 0.42-8.29; P = 0.42), and deep venous thrombosis (RR = 0.97; 95% CI = 0.64-1.47; P = 0.88).
CONCLUSIONS: Tranexamic acid is associated with substantially reduced mortality and growth of hemorrhagic mass in patients with traumatic brain injury, but the need of neurosurgery and extracranial surgery, as well as the risk of unfavorable outcome (GOS) are similar between tranexamic acid and placebo.
参考来源
- Chen H, Chen M. The efficacy of tranexamic acid for brain injury: A meta-analysis of randomized controlled trials. Am J Emerg Med. 2019. PMID: 31706661. doi:10.1016/j.ajem.2019.158499
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。